| Abstrakt: |
Interleukin-11 (IL-11) affects inflammation, motility, and invasion in cancer. Here, we investigated the clinical significance of plasma IL-11 (IL-11p) levels in patients with pancreatic cancer. We enrolled 44 patients with pathologically confirmed diagnoses of pancreatic cancer into this study (median age at diagnosis, 68 years; range, 42-86 years), along with 30 age- and sex-matched healthy controls and 3 patients with pancreatitis complicated with pancreatic cysts and 15 patients with early pancreatitis. Median baseline IL-11p levels of patients with pancreatic cancer were significantly higher than that of the healthy controls ( P < 0.001), as were those of the 15 patients with early pancreatitis. IL-11p levels presented high diagnostic accuracy for pancreatic cancer (area under the curve (AUC), 0.901; sensitivity, 97.7 %; specificity, 70.0 %). Age, sex, lesion site, disease stage, serum dehydrogenase, alkaline phosphatase, γ-glutamyltransferase, and white blood cells, platelets, and hemoglobin levels did not correlate with IL-11p concentrations ( P > 0.05), but patients with distant metastases had lower median IL-11p values than did patients without distant metastases ( P = 0.043). Patients with IL-11p higher than the median level (43.2 pg/mL) had better prognoses than those with lower values ( P = 0.004), particularly as IL-11p concentration increased to ≥50 pg/mL ( P = 0.001). IL-11p concentration correlated with overall survival (≥median IL-11p, 10 months;
|
Full text from SpringerLink